Oral Arsenic With ATRA for Newly Diagnosed Patients With Acute Promyelocytic Leukemia

This study is testing an oral (pill-form) arsenic treatment combined with ATRA (a vitamin A derivative) for newly diagnosed acute promyelocytic leukemia (APL), a specific subtype of blood cancer. Traditional arsenic treatment is given by IV infusion; this study tests whether the oral version works just as well and is more convenient. **You may be eligible if...** - You are between 18 and 75 years old - You have just been diagnosed with acute promyelocytic leukemia (APL), confirmed by genetic testing - Your liver and kidney function are within acceptable limits - Women must use effective contraception or be post-menopausal/surgically sterile **You may NOT be eligible if...** - You are a high-risk patient where your doctor feels chemotherapy is needed - You are younger than 18 or older than 75 - You have significant heart rhythm problems or a long QT interval on your ECG - You have another active cancer at the time of diagnosis - Genetic confirmation of APL is lacking Talk to your doctor to see if this trial is right for you.